Clinics in Dermatology
Volume 24, Issue 5 , Pages 414-429 , September 2006

Cutaneous vasculitis: diagnosis and management

  • J. Andrew Carlson, MD

      Affiliations

    • Division of Dermatology, Albany Medical College, MC-81, Albany, NY 12208, USA
    • Division of Dermatopathology, Albany Medical College, MC-81, Albany, NY 12208, USA
    • Corresponding Author InformationCorresponding author. Division of Dermatology, Albany Medical College, MC-81, Albany, NY 12208, USA. Tel.: +1 518 262 6414; fax: +1 518 262 6251.
    • ,
  • L. Frank Cavaliere, MD

      Affiliations

    • Division of Rheumatology, Albany Medical College, Albany, NY 12208, USA
    • ,
  • Jane M. Grant-Kels, MD

      Affiliations

    • Department of Dermatology and Dermatopathology, University of Connecticut Health Center, Farmington, CT 06030, USA

References 

  1. Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27:504–528
  2. Sorensen SF, Slot O, Tvede N, Petersen J. A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis. 2000;59:478–482
  3. Guillevin L, Lhote F, Amouroux J, Gherardi R, Callard P, Casassus P. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis nodosa group. Br J Rheumatol. 1996;35:958–964
  4. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med. 1998;129:345–352
  5. Jennette CJ, Milling DM, Falk RJ. Vasculitis affecting the skin. A review. Arch Dermatol. 1994;130:899–906
  6. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM. 2005;98:97–111
  7. Lane SE, Watts RA, Barker TH, Scott DG. Evaluation of the Sorensen diagnostic criteria in the classification of systemic vasculitis. Rheumatology (Oxford). 2002;41:1138–1141
  8. Watts RA, Jolliffe VA, Carruthers DM, Lockwood M, Scott DG. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum. 1996;39:1208–1212
  9. Sais G, Vidaller A, Jucgla A, Servitje O, Condom E, Peyri J. Prognostic factors in leukocytoclastic vasculitis: a clinicopathologic study of 160 patients. Arch Dermatol. 1998;134:309–315
  10. Helander SD, De Castro FR, Gibson LE. Henoch-Schonlein purpura: clinicopathologic correlation of cutaneous vascular IgA deposits and the relationship to leukocytoclastic vasculitis. Acta Derm Venereol. 1995;75:125–129
  11. Barnadas MA, Perez E, Gich I, et al. Diagnostic, prognostic and pathogenic value of the direct immunofluorescence test in cutaneous leukocytoclastic vasculitis. Int J Dermatol. 2004;43:19–26
  12. Magro CM, Crowson AN. A clinical and histologic study of 37 cases of immunoglobulin A–associated vasculitis. Am J Dermatopathol. 1999;21:234–240
  13. Stone JH, Nousari HC. “Essential” cutaneous vasculitis: what every rheumatologist should know about vasculitis of the skin. Curr Opin Rheumatol. 2001;13:23–34
  14. Russell JP, Gibson LE. Primary cutaneous small vessel vasculitis: approach to diagnosis and treatment. Int J Dermatol. 2006;45:3–13
  15. Carlson JA, Chen KR. Cutaneous vasculitis update: specific vasculitic syndromes. Am J Dermatopathol. 2006;[in press]
  16. Grau R. Pseudovasculitis: mechanisms of vascular injury and clinical spectrum. Curr Rheumatol Rep. 2002;4:83–89
  17. Gibson LE, Specks U, Homburger H. Clinical utility of ANCA tests for the dermatologist. Int J Dermatol. 2003;42:859–869
  18. Schmitt WH, van der Woude FJ. Clinical applications of antineutrophil cytoplasmic antibody testing. Curr Opin Rheumatol. 2004;16:9–17
  19. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med. 1997;126:866–873
  20. Vassilopoulos D, Niles JL, Villa-Forte A, et al. Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction. Arthritis Rheum. 2003;49:151–155
  21. Watts RA, Jolliffe VA, Grattan CE, Elliott J, Lockwood M, Scott DG. Cutaneous vasculitis in a defined population—clinical and epidemiological associations. J Rheumatol. 1998;25:920–924
  22. Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain. Clinical and epidemiologic aspects. Medicine (Baltimore). 1999;78:292–308
  23. Winkelmann RK, Ditto WB. Cutaneous and visceral syndromes of necrotizing or “allergic” angiitis: a study of 38 cases. Medicine (Baltimore). 1964;43:59–89
  24. Saleh A, Stone JH. Classification and diagnostic criteria in systemic vasculitis. Best Pract Res Clin Rheumatol. 2005;19:209–221
  25. Ratnam KV, Boon YH, Pang BK. Idiopathic hypersensitivity vasculitis: clinicopathologic correlation of 61 cases. Int J Dermatol. 1995;34:786–789
  26. Ioannidou DJ, Krasagakis K, Daphnis EK, Perakis KE, Sotsiou F, Tosca AD. Cutaneous small vessel vasculitis: an entity with frequent renal involvement. Arch Dermatol. 2002;138:412–414
  27. Tancrede-Bohin E, Ochonisky S, Vignon-Pennamen MD, Flageul B, Morel P, Rybojad M. Schonlein-Henoch purpura in adult patients. Predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch Dermatol. 1997;133:438–442
  28. Hodge SJ, Callen JP, Ekenstam E. Cutaneous leukocytoclastic vasculitis: correlation of histopathological changes with clinical severity and course. J Cutan Pathol. 1987;14:279–284
  29. Sanchez NP, Van Hale HM, Su WP. Clinical and histopathologic spectrum of necrotizing vasculitis. Report of findings in 101 cases. Arch Dermatol. 1985;121:220–224
  30. Lerner L, Lio P, Flotte T. The prognostic significance of vascular immunoglobulin deposits in 94 cases of cutaneous leukocytoclastic vasculitis. J Cutan Pathol. 2000;27:562
  31. Sais G, Vidaller A, Servitje O, Jucgla A, Peyri J. Leukocytoclastic vasculitis and common variable immunodeficiency: successful treatment with intravenous immune globulin. J Allergy Clin Immunol. 1996;98:232–233
  32. Mehregan DR, Hall MJ, Gibson LE. Urticarial vasculitis: a histopathologic and clinical review of 72 cases. J Am Acad Dermatol. 1992;26(3 Pt 2):441–448
  33. Davis MD, Daoud MS, Kirby B, Gibson LE, Rogers RS. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol. 1998;38(6 Pt 1):899–905
  34. Sunderkotter C, Seeliger S, Schonlau F, et al. Different pathways leading to cutaneous leukocytoclastic vasculitis in mice. Exp Dermatol. 2001;10:391–404
  35. Kim SH, Kim TB, Yun YS, et al. Hypereosinophilia presenting as eosinophilic vasculitis and multiple peripheral artery occlusions without organ involvement. J Korean Med Sci. 2005;20:677–679
  36. Chen KR, Su WPD, Pittelkow MR, Conn DL, George T, Leiferman KM. Eosinophilic vasculitis in connective tissue disease. J Am Acad Dermatol. 1996;35(2 Pt 1):173–182
  37. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004;199:173–183
  38. Carlson JA, Mihm MC, LeBoit PE. Cutaneous lymphocytic vasculitis: a definition, a review, and a proposed classification. Semin Diagn Pathol. 1996;13:72–90
  39. Haas M, Kraus ES, Samaniego-Picota M, Racusen LC, Ni W, Eustace JA. Acute renal allograft rejection with intimal arteritis: histologic predictors of response to therapy and graft survival. Kidney Int. 2002;61:1516–1526
  40. Mihatsch MJ, Nickeleit V, Gudat F. Morphologic criteria of chronic renal allograft rejection. Transplant Proc. 1999;31:1295–1297
  41. Kao AH, Sabatine JM, Manzi S. Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol. 2003;15:519–527
  42. Luqmani RA, Pathare S, Kwok-Fai TL. How to diagnose and treat secondary forms of vasculitis. Best Pract Res Clin Rheumatol. 2005;19:321–336
  43. Gell P, Coombs R. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963;
  44. Sell S. Immunopathology. In:  Sell S editors. Immunology, immunopathology and immunity. 6th ed. Washington (DC): ASM; 2003;p. 235–239
  45. Arthus M. Injections repetees de serum de cheval chez le lapin. V R Soc Biol. 1903;55:817–820
  46. Wilson CB, Dixon FJ. Quantitation of acute and chronic serum sickness in the rabbit. J Exp Med. 1971;134(3 Suppl):7s–8s
  47. Fernandez HN, Henson PM, Otani A, Hugli TE. Chemotactic response to human C3a and C5a anaphylatoxins: I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978;120:109–115
  48. Baumann U, Kohl J, Tschernig T, et al. A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. J Immunol. 2000;164:1065–1070
  49. Hopken UE, Lu B, Gerard NP, Gerard C. Impaired inflammatory responses in the reverse Arthus reaction through genetic deletion of the C5a receptor. J Exp Med. 1997;186:749–756
  50. Sylvestre DL, Ravetch JV. Fc receptors initiate the Arthus reaction: redefining the inflammatory cascade. Science. 1994;265:1095–1098
  51. Baumann U, Chouchakova N, Gewecke B, et al. Distinct tissue site-specific requirements of mast cells and complement components C3/C5a receptor in IgG immune complex–induced injury of skin and lung. J Immunol. 2001;167:1022–1027
  52. Schiller C, Janssen-Graalfs I, Baumann U, et al. Mouse FcgammaRII is a negative regulator of FcgammaRIII in IgG immune complex–triggered inflammation but not in autoantibody-induced hemolysis. Eur J Immunol. 2000;30:481–490
  53. Kaburagi Y, Hasegawa M, Nagaoka T, et al. The cutaneous reverse Arthus reaction requires intercellular adhesion molecule 1 and l-selectin expression. J Immunol. 2002;168:2970–2978
  54. Zhang Y, Ramos BF, Jakschik BA. Augmentation of reverse Arthus reaction by mast cells in mice. J Clin Invest. 1991;88:841–846
  55. Yanaba K, Kaburagi Y, Takehara K, Steeber DA, Tedder TF, Sato S. Relative contributions of selectins and intercellular adhesion molecule-1 to tissue injury induced by immune complex deposition. Am J Pathol. 2003;162:1463–1473
  56. Yanaba K, Komura K, Horikawa M, Matsushita Y, Takehara K, Sato S. P-Selectin glycoprotein ligand-1 is required for the development of cutaneous vasculitis induced by immune complex deposition. J Leukoc Biol. 2004;76:374–382
  57. Burrows NP, Molina FA, Terenghi G, et al. Comparison of cell adhesion molecule expression in cutaneous leucocytoclastic and lymphocytic vasculitis. J Clin Pathol. 1994;47:939–944
  58. Sais G, Vidaller A, Jucgla A, Condom E, Peyri J. Adhesion molecule expression and endothelial cell activation in cutaneous leukocytoclastic vasculitis. An immunohistologic and clinical study in 42 patients. Arch Dermatol. 1997;133:443–450
  59. Bielsa I, Carrascosa JM, Hausmann G, Ferrandiz C. An immunohistopathologic study in cutaneous necrotizing vasculitis. J Cutan Pathol. 2000;27:130–135
  60. Cid MC, Cebrian M, Font C, et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum. 2000;43:184–194
  61. Coll-Vinent B, Cebrian M, Cid MC, et al. Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum. 1998;41:435–444
  62. Inaloz HS, Evereklioglu C, Unal B, Kirtak N, Eralp A, Inaloz S. The significance of immunohistochemistry in the skin pathergy reaction of patients with Behcet's syndrome. J Eur Acad Dermatol Venereol. 2004;18:56–61
  63. Kano Y, Orihara M, Shiohara T. Cellular and molecular dynamics in exercise-induced urticarial vasculitis lesions. Arch Dermatol. 1998;134:62–67
  64. Sais G, Vidaller A. Pathogenesis of exercise-induced urticarial vasculitis lesions: can the changes be extrapolated to all leukocytoclastic vasculitis lesions?. Arch Dermatol. 1999;135:87–89
  65. Cid MC. Endothelial cell biology, perivascular inflammation, and vasculitis. Cleve Clin J Med. 2002;69(Suppl 2):SII45–SII49
  66. Hernandez-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004;43:294–301
  67. Papi M, Didona B, De Pita O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol. 1998;134:447–452
  68. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest. 2002;110:955–963
  69. Day CJ, Hewins P, Savage CO. New developments in the pathogenesis of ANCA-associated vasculitis. Clin Exp Rheumatol. 2003;21(6 Suppl 32):S35–S48
  70. Marinaki S, Neumann I, Kalsch AI, et al. Abnormalities of CD4 T cell subpopulations in ANCA-associated vasculitis. Clin Exp Immunol. 2005;140:181–191
  71. Cid MC, Segarra M, Garcia-Martinez A, Hernandez-Rodriguez J. Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. Curr Rheumatol Rep. 2004;6:184–194
  72. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143:632–638
  73. Kelly RI, Opie J, Nixon R. Golfer's vasculitis. Australas J Dermatol. 2005;46:11–14
  74. Ryan T. Cutaneous vasculitis. In:  Champion R,  Burton J,  Burns D,  Breathnach SM editor. Textbook of dermatology. 6th ed. Oxford: Blackwell Scientific Publications; 1998;p. 2155–2225
  75. Prins M, Veraart JC, Vermeulen AH, Hulsmans RF, Neumann HA. Leucocytoclastic vasculitis induced by prolonged exercise. Br J Dermatol. 1996;134:915–918
  76. Langford CA. 15. Vasculitis. J Allergy Clin Immunol. 2003;111(2 Suppl):S602–S612
  77. Jennette JC. Implications for pathogenesis of patterns of injury in small- and medium-sized–vessel vasculitis. Clevel Clin J Med. 2002;69(Suppl 2):SII33–SII38
  78. Harper L, Williams JM, Savage CO. The importance of resolution of inflammation in the pathogenesis of ANCA-associated vasculitis. Biochem Soc Trans. 2004;32:502–506
  79. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med. 2005;352:330–332
  80. Buckley CD, Rainger GE, Nash GB, Raza K. Endothelial cells, fibroblasts and vasculitis. Rheumatology (Oxford). 2005;44:860–863
  81. Mekkes JR, Loots MA, van der Wal AC, Bos JD. Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol. 2004;50:104–107
  82. Claudy A. Coagulation and fibrinolysis in cutaneous vasculitis. Clin Dermatol. 1999;17:615–618
  83. Tomizawa K, Sato-Matsumura KC, Kajii N. The coexistence of cutaneous vasculitis and thrombosis in childhood-onset systemic lupus erythematosus with antiphospholipid antibodies. Br J Dermatol. 2003;149:439–441
  84. Rocca PV, Siegel LB, Cupps TR. The concomitant expression of vasculitis and coagulopathy: synergy for marked tissue ischemia. J Rheumatol. 1994;21:556–560
  85. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum. 2006;55:146–149
  86. Rees JD, Lanca S, Marques PV, et al. Prevalence of the antiphospholipid syndrome in primary systemic vasculitis. Ann Rheum Dis. 2006;65:109–111
  87. Diaz-Perez JL, Schroeter AL, Winkelmann RK. Cutaneous periarteritis nodosa: immunofluorescence studies. Arch Dermatol. 1980;116:56–58
  88. Drenkard C, Villa AR, Reyes E, Abello M, Alarcon-Segovia D. Vasculitis in systemic lupus erythematosus. Lupus. 1997;6:235–242
  89. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol. 2003;48:311–340
  90. Gonzalez-Gay MA, Garcia-Porrua C, Pujol RM. Clinical approach to cutaneous vasculitis. Curr Opin Rheumatol. 2005;17:56–61
  91. Luqmani RA. Is it possible to offer evidence-based treatment for systemic vasculitis?. Scand J Rheumatol. 2000;29:211–215
  92. Russell JP, Weenig RH. Primary cutaneous small vessel vasculitis. Curr Treat Options Cardiovasc Med. 2004;6:139–149
  93. Callen JP. A clinical approach to the vasculitis patient in the dermatologic office. Clin Dermatol. 1999;17:549–553
  94. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671–678
  95. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol. 1998;37:57–63
  96. Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol. 1993;20:289–298
  97. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341–347
  98. Callen JP, Ekenstam E. Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. South Med J. 1987;80:848–851
  99. Ramelli GP, Bianchetti MG. Dapsone in cutaneous Henoch-Schonlein syndrome—worth a trial. Acta Paediatr. 1997;86:337
  100. Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol. 1987;16:772–778
  101. Callen JP. Colchicine is effective in controlling chronic cutaneous leukocytoclastic vasculitis. J Am Acad Dermatol. 1985;13(2 Pt 1):193–200
  102. Nurnberg W, Grabbe J, Czarnetzki BM. Synergistic effects of pentoxifylline and dapsone in leucocytoclastic vasculitis. Lancet. 1994;343:491
  103. Nurnberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol. 1995;75:54–56
  104. Sais G, Vidaller A, Jucgla A, Gallardo F, Peyri J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol. 1995;131:1399–1402
  105. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267–279
  106. Ferri C, Pietrogrande M, Cecchetti R, et al. Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia. Am J Med. 1989;87:519–524
  107. Lunardi C, Bambara LM, Biasi D, Zagni P, Caramaschi P, Pacor ML. Elimination diet in the treatment of selected patients with hypersensitivity vasculitis. Clin Exp Rheumatol. 1992;10:131–135
  108. Cupps TR, Springer RM, Fauci AS. Chronic, recurrent small-vessel cutaneous vasculitis. Clinical experience in 13 patients. JAMA. 1982;247:1994–1998
  109. Quintana G, Matteson EL, Fernandez A, Restrepo JF, Iglesias A. Localized nodular vasculitis: a new variant of localized cutaneous polyarteritis nodosa?. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S31–S34
  110. Jorizzo JL, White WL, Wise CM, Zanolli MD, Sherertz EF. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behcet's disease. J Am Acad Dermatol. 1991;24(6 Pt 1):973–978
  111. Williams HC, Pembroke AC. Methotrexate in the treatment of vasculitic cutaneous ulceration in rheumatoid arthritis. J R Soc Med. 1989;82:763
  112. Upchurch KS, Heller K, Bress NM. Low-dose methotrexate therapy for cutaneous vasculitis of rheumatoid arthritis. J Am Acad Dermatol. 1987;17(2 Pt 2):355–359
  113. Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1994;21:1674–1677
  114. Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997;56:382–385
  115. ten Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother. 2002;36:130–147
  116. Kaye O, Beckers CC, Paquet P, Arrese JE, Pierard GE, Malaise MG. The frequency of cutaneous vasculitis is not increased in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol. 1996;23:253–257
  117. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol. 1991;127:515–522
  118. Martinez-Taboada VM, Blanco R, Garcia-Fuentes M, Rodriguez-Valverde V. Clinical features and outcome of 95 patients with hypersensitivity vasculitis. Am J Med. 1997;102:186–191
  119. Lopez LR, Davis KC, Kohler PF, Schocket AL. The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine. J Allergy Clin Immunol. 1984;73(5 Pt 1):600–603
  120. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus. 1998;7:80–85
  121. Tosca AD, Ioannidou DJ, Katsantonis JC, Kyriakis KP. Cyclosporin A in the treatment of cutaneous vasculitis. Clinical and cellular effects. J Eur Acad Dermatol Venereol. 1996;6:135–141
  122. Stratigos JD, Katsambas A, Potouridou E. Cyclosporin—a therapy for allergic cutaneous vasculitis. J Dermatol Treat. 1994;5:93–95
  123. de Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol. 2005;64:480–484
  124. Singh S, Devidayal , Kumar L, Joshi K, Minz RW, Datta U. Severe Henoch-Schonlein nephritis: resolution with azathioprine and steroids. Rheumatol Int. 2002;22:133–137
  125. Worm M, Sterry W, Kolde G. Mycophenolate mofetil is effective for maintenance therapy of hypocomplementaemic urticarial vasculitis. Br J Dermatol. 2000;143:1324
  126. Gaskin G, Pusey CD. Plasmapheresis in antineutrophil cytoplasmic antibody–associated systemic vasculitis. Ther Apher. 2001;5:176–181
  127. Turner AN, Whittaker S, Banks I, Jones RR, Pusey CD. Plasma exchange in refractory cutaneous vasculitis. Br J Dermatol. 1990;122:411–415
  128. Gedalia A, Sorensen R. Intravenous immunoglobulin in childhood cutaneous polyarteritis nodosa. Clin Exp Rheumatol. 1998;16:767
  129. Ong CS, Benson EM. Successful treatment of chronic leucocytoclastic vasculitis and persistent ulceration with intravenous immunoglobulin. Br J Dermatol. 2000;143:447–449
  130. Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?. Clin Rev Allergy Immunol. 2005;29:237–245
  131. Buhaescu I, Covic A, Levy J. Systemic vasculitis: still a challenging disease. Am J Kidney Dis. 2005;46:173–185
  132. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis. Ann Rheum Dis. 2005;64(Suppl 4):iv31–iv36
  133. Lamprecht P. TNF-alpha inhibitors in systemic vasculitides and connective tissue diseases. Autoimmun Rev. 2005;4:28–34
  134. Cohen SB. B-Cell depletion for rheumatic diseases: where are we?. Med Gen Med. 2005;7:72
  135. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 “what do B-cells do?”. Clin Immunol. 2005;117:207–213
  136. Raza K, Carruthers DM, Stevens R, Filer AD, Townend JN, Bacon PA. Infliximab leads to a rapid but transient improvement in endothelial function in patients with primary systemic vasculitis. Ann Rheum Dis. 2006;65:946–948
  137. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109:1718–1723
  138. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford). 2002;41:1303–1307
  139. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti–TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford). 2002;41:1126–1132
  140. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody–associated systemic vasculitis. J Am Soc Nephrol. 2004;15:717–721
  141. van der Bijl AE, Allaart CF, Van Vugt J, Van Duinen S, Breedveld FC. Rheumatoid vasculitis treated with infliximab. J Rheumatol. 2005;32:1607–1609
  142. Uthman IW, Touma Z, Sayyad J, Salman S. Response of deep cutaneous vasculitis to infliximab. J Am Acad Dermatol. 2005;53:353–354
  143. Leiba M, Ehrenfeld M. Behcet's disease: current therapeutic perspectives. Curr Treat Options Cardiovasc Med. 2005;7:139–148
  144. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis–associated foot-drop with infliximab. J Rheumatol. 2005;32:759;[author reply 759-60]
  145. Mang R, Ruzicka T, Stege H. Therapy for severe necrotizing vasculitis with infliximab. J Am Acad Dermatol. 2004;51:321–322
  146. Chandesris MO, Gayet S, Schleinitz N, Doudier B, Harle JR, Kaplanski G. Infliximab in the treatment of refractory vasculitis secondary to hepatitis C–associated mixed cryoglobulinaemia. Rheumatology (Oxford). 2004;43:532–533
  147. Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. Ann Rheum Dis. 2003;62:587–588
  148. Gulli S, Arrigo C, Bocchino L, et al. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord. 2003;4:19
  149. Garcia-Porrua C, Gonzalez-Gay MA. Successful response to infliximab in a patient with undifferentiated spondyloarthropathy coexisting with polyarteritis nodosa–like cutaneous vasculitis. Clin Exp Rheumatol. 2003;21(6 Suppl 32):S138
  150. Stone JH. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352:351–361
  151. Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol. 2005;11:219–222
  152. Atzeni F, Sarzi-Puttini P, Capsoni F, Mecchia M, Marrazza MG, Carrabba M. Successful treatment of resistant Behcet's disease with etanercept. Clin Exp Rheumatol. 2005;23:729
  153. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98–105
  154. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. Ann Rheum Dis. 2003;62:373–374
  155. Scheinberg MA. Treatment of recurrent oral aphthous ulcers with etanercept. Clin Exp Rheumatol. 2002;20:733–734
  156. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101:3827–3834
  157. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood. 2003;101:3818–3826
  158. Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR. Remission of refractory hepatitis C–negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant. 2005;20:213–216
  159. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody–positive vasculitis successfully treated with rituximab. J Intern Med. 2005;257:540–548
  160. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med. 2006;173:180–187
  161. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum. 2005;52:262–268
  162. Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol. 2006;18:54–63
  163. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant. 2004;19:3054–3061
  164. Saigal K, Valencia IC, Cohen J, Kerdel FA. Hypocomplementemic urticarial vasculitis with angioedema, a rare presentation of systemic lupus erythematosus: rapid response to rituximab. J Am Acad Dermatol. 2003;49(5 Suppl):S283–S285
  165. Guillevin L, Mouthon L. Tumor necrosis factor–alpha blockade and the risk of vasculitis. J Rheumatol. 2004;31:1885–1887
  166. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol. 2005;61:329–336
  167. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti–tumor necrosis factor–alpha therapy–induced vasculitis: case series. J Rheumatol. 2003;30:2287–2291
  168. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor–alpha blocking agents. J Rheumatol. 2004;31:1955–1958
  169. Kandula P, Kouides PA. Rituximab-induced leukocytoclastic vasculitis: a case report. Arch Dermatol. 2006;142:246–247
  170. Dereure O, Navarro R, Rossi JF, Guilhou JJ. Rituximab-induced vasculitis. Dermatology. 2001;203:83–84

PII: S0738-081X(06)00099-X

doi: 10.1016/j.clindermatol.2006.07.007

Clinics in Dermatology
Volume 24, Issue 5 , Pages 414-429 , September 2006

Article Tools

* Image Usage & Resolution